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The circulating, endocrine renin-angiotensin system (RAS) is important to circulatory homeostasis, while
ubiquitous tissue and cellular RAS play diverse roles, including metabolic regulation. Indeed, inhibition of
RAS is associated with improved cellular oxidative capacity. Recently it has been suggested that an
intra-mitochondrial RAS directly impacts on metabolism. Here we sought to rigorously explore this
hypothesis. Radiolabelled ligand-binding and unbiased proteomic approaches were applied to purified
mitochondrial sub-fractions from rat liver, and the impact of AngII on mitochondrial function assessed.
Whilst high-affinity AngII binding sites were found in the mitochondria-associated membrane (MAM)
fraction, no RAS components could be detected in purifiedmitochondria. Moreover, AngII had no effect on
the function of isolatedmitochondria at physiologically relevant concentrations.We thus found no evidence
of endogenous mitochondrial AngII production, and conclude that the effects of AngII on cellular energy
metabolism are not mediated through its direct binding to mitochondrial targets.
T
he circulating (endocrine) renin-angiotensin system (RAS) plays a key role in human circulatory home-
ostasis. Hepatically-derived angiotensinogen is cleaved by the aspartyl protease renin of renal juxtaglomer-
ular origin to yield the inert decapeptide angiotensin I (AngI). Circulating or endothelially-bound
angiotensin-I converting enzyme (ACE) converts AngI to octapeptide angiotensin II (AngII), which promotes
renal salt andwater retention (through aldosterone released from the adrenal gland), whilst also causing arteriolar
vasoconstriction. In these ways, the endocrine RAS promotes intravascular fluid retention and help maintain
arterial blood pressure1. Meanwhile, ubiquitous local tissue RAS synthesise AngII which acts on adjacent cells
(paracrine actions), on the surface of the synthesizing cell itself (autocrine actions), or on intracellular receptors,
often found in the nucleus (intracrine actions). Such local RAS may be complete, or dependent for their function
on the uptake of some critical RAS components from the circulation, with some cells internalising exogenous
AngII, and others synthesising it de novo2–5. Whether of local or systemic origin, AngII mediates its effects
through action at two receptor subtypes. While the role of its type-2 receptor (AT2R) is less clear, the type-1
receptor (AT1R) mediates diverse responses, amongst them the regulation of inflammation, fibrosis, cell growth
and survival6,7.
Recent studies suggest that AngII may also play an important role in the regulation of cellular energy meta-
bolism. In humans, genetically-determined lower ACE activity is associated with enhanced efficiency, reduced
oxygen consumption per unit of external work and a relative conservation of fat stores during exercise, as well as
with increased performance in hypoxic environments8–12. In rodents, combined ACE inhibition and AT1R
antagonism reduce renal oxygen consumption related to sodium transport13, while infusion of AngII increases
oxygen consumption in different tissues14,15. In addition, AngII has been shown to modulate mitochondrial
membrane potential, expression of uncoupling proteins and transcription of respiratory chain subunits, and
to trigger the generation of reactive oxygen species (ROS)16–18.
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Mitochondrial effects of AngII might be mediated by activation of
cellular signalling pathways through AngII action on cell surface
receptors6,19. Alternatively, AngII may have direct effects upon mito-
chondria, given that AngII and AT1Rs have been observed on the
outer mitochondrial membrane (OMM)20,21, and that exogenously-
administered 3H-labelled AngII has been shown to traffic to the
surface of rodent mitochondria22. In addition, however, it has also
been suggested that a bona fide intra-mitochondrial RASmight exist,
capable of de novo AngII synthesis. Interest in the existence of such a
system has increased by a recent report which suggested the presence
of AT2Rs on the inner mitochondrial membrane23. However, this
conclusion was largely based upon the use of AT2R antibodies whose
specificity was untested in this context, and on non-quantitative
imaging.
We thus sought to further explore the presence of a mitochondrial
RAS through the application of unbiased proteomic approaches and
radiolabelled ligand binding in highly purified mitochondrial frac-
tions from rat liver, together with mitochondrial functional assays.
Our results exclude the presence of intramitochondrial AT receptors
and other components of RAS, but show that AT1R are present in the
MAM. Specific binding of AngII to these receptors did not elicit
physiological effects on mitochondrial respiration in isolated liver
mitochondria, contesting the generalised relevance of direct mito-
chondrial actions of RAS.
Results
Mass spectrometry and in silico analysis of the mitochondrial
proteome do not verify the existence of a mitochondrial RAS.
First, in order to obtain unbiased evidence for the presence of RAS
in mitochondria, we used purified mitochondrial fractions for
proteomic analysis. The Crude mitochondrial fraction (CM), along
with nuclei, microsomes, lysosomes and cytoplasm were purified by
differential centrifugation. From the CM fraction, pure mito-
chondria (PM) were separated from mitochondria associated
membranes (MAM), using isopicnic ultracentrifugation on a self-
forming Percoll density gradient from rat livers24. TheMAM fraction
represents the interface of mitochondria with other cellular
organelles, in particular the endoplasmic reticulum (ER), where
signalling and metabolic interactions take place. It thus contains
components of the OMM and other loosely associated cellular
membranes. In contrast, pure mitochondria are devoid of other
organelles, and highly enriched in matrix, IMM, OMM and
intermembrane space components (for recent reviews see25,26).
Proteins from the CM, PM and MAM fractions were separated by
SDS-PAGE and subjected to mass spectrometry analysis (Supple-
mentary Fig. S1 and Supplementary Dataset S1). We compiled a
list of RAS-related genes using the AmiGO gene ontology (GO)
database, and sought the presence of their transcription products
amongst those identified by mass spectrometry analysis.
Importantly, from the three RAS related components found in the
CM and MAM and PM fractions, none is involved directly in
angiotensin generation and binding (see Supplementary Dataset S1).
The validity of these findings is supported by interrogation of
unbiased catalogues of the mitochondrial proteome. The MitoMiner
database aggregates findings from 47 proteomic surveys across several
species27, while MitoCarta combines proteomics, imaging and
sequence analysis to score the probability of mitochondrial local-
ization of individual proteins in humans and mouse, further increas-
ing the sensitivity to identify mitochondrial proteins28. In addition to
our proteomic analysis in rat liver, the use of these databases allowed
us to test the presence of RAS components and all related genes from
a series of mammalian species and tissues, including rodent, bovine
and human gene sets (Supplementary Dataset S2). Again, we gener-
ated gene sets from those belonging to all RAS related GO terms in
the AmiGO database across all species. We then searched against the
predicted mitochondrial genes in the MitoMiner and MitoCarta
databases. This revealed mitochondrial localization of gene products
involved in aldosterone synthesis, as targets of RAS, but no intrinsic
RAS components have been experimentally proven or were bioinfor-
matically predicted to localize to mitochondria (Supplementary
Dataset S2).
While these approaches together rendered the presence of RAS in
themitochondria unlikely, they cannot formally exclude the possibil-
ity of the presence of components at low abundance. Thus, we pro-
ceeded to analyse the purified mitochondrial sub-fractions for the
presence of main RAS components using immunoprecipitation and
immunoblotting.
Rat liver mitochondria do not contain detectable ACE. If a functi-
onal, self-sufficient RAS exists in mitochondria, it should contain
enzymes generating AngII, a role mostly fulfilled by ACE, the most
evolutionarily conserved enzyme, which is directly responsible for
the generation of AngII from AngI throughout the body. We thus
sought to identify ACE in purifiedmitochondria from rat liver tissue.
As shown in Fig. 1A, an antibody directed to the C-terminus of the
protein recognised a high molecular weight band (MW< 150 kDa,
predicted MW of ACE) in the homogenate, nuclear, lysosomal and
microsomal fractions, but not in mitochondria. Conversely, a low
MW (<50 kDa) band was enriched in the crude mitochondrial
fraction. This band was also present in the pure mitochondrial
fractions from three independent preparations albeit at lower and
variable intensity. Since a shorter natural human and rat ACE
isoform exists (ACE-T, Uniprot P47820), we sought to confirm the
identity of the lowerMWmitochondrial band.We thus purified it by
immunoprecipitation (Fig. 1B) and analysed by mass spectrometry.
However, the results of the analysis did not return any ACE related
sequences, indicating that the band represents non-specific binding
by the antibody. Altogether, these results confirmed the proteomic
analysis excluding the presence of ACE in mitochondria.
AT1R is present in theMAM, but noAT1R, AT2R or AngII binding
is detectable in the PM fraction.Whilst the previous results excluded
the possibility of intra-mitochondrial generation of AngII by ACE,
mitochondria can still be the target of AngII generated at other
intracellular sites or imported from extracellular sources. We there-
fore sought the presence of functional AngII receptors in rat liver
subcellular and submitochondrial fractions, using two independent
strategies. First, we measured specific binding of [125I]-AngII in the
PM and MAM fractions. As shown in Fig. 2A, we detected a single
high affinity binding site in the MAM fraction as indicated by Hill
slopes close to unity, with a subnanomolar equilibrium dissociation
constant (KD) and a maximal receptor density (Bmax) comparable to
the range found in the plasma membrane29, indicating that functional
AngII binding sites are present in mitochondria associated mem-
branes. However, the same high affinity binding sites showed < 50
times less density in purified mitochondria, most likely indicating
contamination from the MAM fraction, and unlikely to be
consistent with efficient AngII mediated signalling. Binding of AngII
to theMAM-localized binding sites was inhibited by the specific AT1R
antagonist Losartan, but not affected by the AT2R antagonist
PD123319, indicating that binding was AT1R-related (Fig. 2B).
In order to further analyse the presence and localization of AT1R
and AT2R subtypes, we next performed Western blot analysis of the
rat liver subcellular and sub-mitochondrial fractions. In agreement
with the binding studies, we were able to detect AT1R in the CM and
MAM fraction, but not in the PM (Fig. 2C). In contrast, antibodies
against AT2R gave a series of immunoreactive bands (Fig. 3A), even
in the expected molecular weight range of the receptor (<40–50 kD;
Fig. 3B). Thus we followed the strategy previously applied to ACE,
using the antibody to immunoprecipitate its binding partners and
identified the resulting proteins by mass spectrometry. Immunopre-
cipitation with the anti-AT2R antibody pulled down three bands in
the range of 30–70 kD in the MAM and partly in the PM fraction
www.nature.com/scientificreports
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(Fig. 3C). However, mass spectrometry identified these bands as
unrelated proteins.
Together, these results confirm the lack of functional AngII recep-
tors in rat liver mitochondria, but raised the possibility that intracel-
lular AngII might alter mitochondrial function through agonist
action at receptors located on the MAM.We thus performed further
experiments using purified crude mitochondria (which contain pure
mitochondria and their associated membranes) and evaluated the
effect of AngII on oxidative phosphorylation.
AngII exerts marginal inhibition on respiration of isolated
mitochondria at supra-physiological concentrations. Physiological
concentrations of AngII in the plasma are in the picomolar range, in
accordance with the sub-nanomolar affinity of angiotensin receptors
on the cell surface. We have found AT1Rs with similarly high affinity
in the MAM fraction. Tissue AngII levels vary from picomolar to the
low nanomolar range depending on tissue type and conditions30,31,
while no intracellular concentrations of AngII have been reported so
far. Thus, we analysed the effect of AngII on isolated mitochondria
(crude mitochondrial fraction, containing both the PM and MAM
sub-fractions) in a broad concentration range. Supra-physiological
(1 mM) saturating AngII had no significant effect on basal endo-
genous mitochondrial respiration rate (5 to 25 min in the absence
of exogenous substrates and ADP) as compared to controls
(Figure 4A and Supplementary Figure S2). Similarly, acute addition
of AngII, using concentrations in the physiological range (10–
100 nM) had no effect on the activity of complexes I and II in the
presence of substrates and ADP (state 3 respiration, Fig. 4B–D).
Finally, we applied AngII in the range of 1 nM-1 mM range for
20 min and measured the state 3 activities of complexes I, II and
IV (Fig. 4E–G). Again, AngII exerted no significant effect on
respiration when applied in the physiological range (1–100 nM),
while 1 mM AngII induced a minor but significant reduction in the
maximal ADP-stimulated complex I-, II, and IV-dependent state 3
respiration. These results suggest that AngII does not exert a specific
effect on oxidative phosphorylation in mitochondria isolated from rat
liver, but might target non-specific binding sites at supra-
physiological concentrations.
Figure 1 | Mitochondrial subfractions lack detectable ACE. (A). Western blot using anti ACE and anti-grp75 antibodies from rat liver subcellular
fractions. H-homogenate, N-nuclear fraction, C-cytosol, L-lysosomes, Mc-microsomes. Rat liver mitochondria were purified by differential
centrifugation to obtain crudemitochondria (CM) and further separated to mitochondria associatedmembranes (MAM) and pure mitochondrial (PM)
fractions by isopicnic Percoll centrifugation (for details see Methods). Mitochondrial fractions contain only a non-canonical 50 kDa immunoreactive
band. Images of immunoblots were cropped to delineate the regions of interest. For the two immunoblots different aliquots of the same samples were
loaded and separated under identical conditions. See full images on Supplementary Figure S3. (B). Immunoprecipitation of ACE using the CM fraction as
input using the Pierce Crosslink IP approach as described in Methods. 10 mg ACE C-20 antibody was crosslinked to the protein A/G agarose resin and
1 mg protein was used as input. The immunoprecipitation was performed either in Tris-Buffered Saline, (TBS, 0.025 M Tris, 0.15 M NaCl; pH 7.2) or
TBS supplementedwith 0.5 mMEDTA, 0.5%NP-40, 2.5% glycerol to promote ACE binding (D). An unrelated goat antibody (UR) and the resin without
antibody crosslinked (R) were used as controls in both TBS and D solutions. Upper panel shows immunodetection using the same ACE antibody, lower
panel shows silver stained SDS-PA gels. The 50 kDa band in the ACE-D fraction has been analysed by mass spectrometry, and identified as a non-ACE or
RAS related protein. Images were cropped to show all visible bands.
Figure 2 | AT1R is present in the MAM fraction. (A). Affinity (KD),
density (BMAX) and cooperativity (Hill coefficient, nH) of specific AngII
binding sites in the PM andMAM fractions. (B). Specific binding of [125I]-
AngII in the MAM fraction in the presence of AT1R (losartan) or AT2R
(PD123319) blockers. The concentration of losartan was calculated from
inhibition constants29 to block .95% of the AT1 receptor but ,2% of
AT2R. [PD123319] was calculated to block 99% of AT2R but ,2% of
AT1R. (C). Western blot detection of AT1R in subcellular fractions. H-
homogenate, C-cytosol, L-lysosomes, Mc-microsomes. Rat liver
mitochondria were purified by differential centrifugation (CM) and
further separated to mitochondria associated membranes (MAM) and
puremitochondrial (PM) fractions by isopicnic Percoll centrifugation (for
details seeMethods). Cytochrome oxidase subunit IV (CoxIV) was used as
mitochondrial inner membrane marker. Images of immunoblots were
cropped to delineate the regions of interest. The same membrane was used
for both immunoblots. See full images on Supplementary Figure S4.
www.nature.com/scientificreports
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Discussion
In view of the accumulating evidence of metabolic effects of the
circulating and local RAS in mammals, it is an attractive hypothesis
that intracrine RAS evolved to directly influencemitochondrial func-
tion. To test this assumption we have considered two scenarios.
First, previous work suggested that mitochondria might contain a
fully functional RAS leading to intra-mitochondrial generation of
AngII. A truncated prorenin, generated by alternative splicing, was
shown to contain mitochondrial targeting sequences and to be de
facto imported into isolated mitochondria32. Moreover, intra-mito-
chondrial ‘dense bodies’ were shown to contain renin using immu-
nogold labelling and electron microscopy (EM)33, together with
angiotensinogen and AngII34. However, the presence of these RAS
components appears to be limited to certain tissues and conditions,
particularly to the adrenal cortex following nephrectomy (for a
review see ref. 35). Such an intracellular RAS system has been pro-
posed to serve as a local amplifier of RAS signalling, reducing the
requirement for circulating AngII, and stimulating aldosterone
secretion36. Indeed, renin co-localizes with several steroid synthesis
enzymes in the mitochondria, but the exact function of mitochon-
drial RAS components in this tissue has not yet been clarified. In
addition, a study using Percoll gradient purification of crude mito-
chondria localised ‘dense bodies’ with functional renin activity in a
mitochondria associated membrane fraction37, and close inspection
of EM images from the previous references also show scattered dis-
tribution of immunogold labelling around mitochondria. Thus, to
clarify whether RAS is a general component of the mitochondrial
proteome, we have carried out unbiased proteomic and in silico
analyses of all known RAS components and functionally related
proteins. In addition, we particularly chose to evaluate the presence
or absence of ACE in mitochondria for two reasons: (i) ACE repre-
sents the final essential step in AngII generation and (ii) ACE ortho-
logs have been detected in several bacterial species, making it the
most likely candidate to be present in the ancestors of mitochondria
according to the endosymbiontic theory, in contrast to the rest of the
RAS components, which appeared rather late in vertebrate evolution,
in parallel with the development of the juxtaglomerular apparatus in
Osteichthyes (e.g. zebrafish)38. Our results, including mass spectro-
metry, bioinformatics and immunoprecipitation/Western blot ana-
lyses, provided no support at all to the idea of a full-blown RAS
operating in the mitochondrion of liver cells. Since dual, cytoplas-
mic/nuclear vs. mitochondrial localisation of a surprisingly large
fraction of the proteome has been recently predicted39, we cannot
exclude that under certain conditions and in specific tissues RAS
components might be imported into the mitochondrion, but the
functional consequences of such an event remains obscure.
The second scenario is based on the currently widely held idea that
intracrine signalling networks, including a range of peptide hor-
mones, growth factors and enzymes (for a detailed list see e.g. a recent
review by Re & Cook18), are targeting the nucleus and mitochondria
to alter cellular function. In the case of AngII, this can occur by
activation of nuclear receptors: nuclear targeting of AngII was
already reported in the early 1970’s22, and later confirmed by several
groups in a range of tissues, along with AT1Rs20,21,40. Whilst the
functional role of the nuclear binding of still remains still to be
clarified, a number of recent observations suggest that AngII alters
mitochondrial function. It is thus important to localise the target of
AngII and to understand its mechanism of action. The best charac-
terised pathway of AngII action on mitochondria via plasma mem-
brane AT1R receptors is linked to intracellular Ca21 mobilisation
following Ca21 release from endoplasmic reticulum Ca21 stores19.
The ensuing accumulation of Ca21 in mitochondria can exert acute
activation of the Krebs cycle and OXPHOS41, but chronic activation
of the pathway may lead to mitochondrial Ca21 overload, depolar-
isation and reduced ATP production42,43. Parallel to Ca21 signalling,
multiple pathways are activated by both AT1R and AT2R, including
MAPK and reactive oxygen species (ROS) generation, which can
contribute to AngII mediated mitochondrial dysfunction6,44. Finally,
however, intracellularly-generated or imported AngII might directly
act on mitochondria. Thus, in addition to detailed proteomic ana-
lysis, we tested this hypothesis by probing direct binding of AngII to
mitochondrial sub-fractions and evaluating the functional effect of
AngII on isolated liver mitochondria. Our results argue against a
Figure 3 | Lack of an AT2R specific immunoreactive band in rat liver
mitochondria. (A). Immunoreactive bands detected by the sc9040, rabbit
AT2R antibody in subcellular fractions: H-homogenate, C-cytosol, L-
lysosomes, Mc-microsomes. Rat liver mitochondria were purified by
differential centrifugation (CM) and further separated to mitochondria
associated membranes (MAM) and pure mitochondrial (PM) fractions by
isopicnic Percoll centrifugation (for details see Methods). For
immunoblotting the same membrane was used as in Fig. 2C. Images were
cropped to show all visible bands. The bands appearing, 15 kD represent
CoxIV staining. (B). The method reveals several bands also in around the
predicted molecular weight of AT2R. The AT2R panel was cropped from
(A). Cytochrome oxidase subunit IV (CoxIV) was used as mitochondrial
inner membrane marker, immunoblotted from the same membrane as
used in (A) and Fig. 2C. The full images are shown in Supplementary Fig.
S4. (C). AT2R immunoprecipitations from all subcellular fractions and IgG
controls separated by SDS PAGE and stained with Coomassie-blue. To
maintain integrity of IgG at 130 kDa, we used a non-denaturating 43
loading buffer without dithiothreitol and b-mercaptoethanol (200 nM
Tris HCl pH 6.8, 8% SDS, 40% glycerol, 0.1% bromophenol blue). Three
immunoprecipitated bands from theMAM fraction (red circles) have been
identified by mass spectrometry as non-RAS related proteins. Images were
cropped to show all bands.
www.nature.com/scientificreports
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generalised view of direct action of AngII on the organelle: pure
mitochondria did not significantly express specific AngII binding
sites, while only marginal inhibition of OXPHOS could be observed,
and this at very high [AngII].
Interestingly, AT1Rs could be found at high density in the MAM
fraction, but their origin and functional relevance is uncertain. It is
possible that they represent internalised plasma membrane receptors
transiently associated withmembranes co-purifying withmitochondria
during intracellular trafficking. Certainly they appear dissociated from
downstream signalling with functional relevance to themitochondrion,
since AngII was unable to alter mitochondrial function in our studies of
the CM fraction.
Our findings are somewhat in conflict with a recent study arguing
for the presence of functional AT2Rs onmitochondria from rat heart
and liver23. We have extensively tested the specificity of the antibody
used in their study. As shown on Fig. 2, the antibody labels several
Figure 4 | The effect of AngII on respiration of isolated liver mitochondria. (A). Basal oxygen consumption of isolated rat liver mitochondrial 5 min
after transfer to the respiration chamber, and at 5, 10, 15, 20 and 25 minutes after addition of AngII (1 mM) (n 5 18). (B–D). ADP-induced oxygen
consumption of isolated rat livermitochondria for complexes I and II, with andwithout (control) acute addition of AngII at the indicated concentrations.
Data are summarized on panel (B). (C) and (D) show individual representative traces from 9 experiments from 3 independent preparations. (E–G). ADP-
induced oxygen consumption of isolated rat liver mitochondria for complexes I, II and IV after 20 minutes of incubation with and without (control)
AngII for 20 min (n5 9 (1–100 nM); n5 16 (1 mM)). Data represent mean 6SEM. Statistical analysis: for basal respiration rates, differences along time
between samples were assessed by ANOVA for repeated measures (time-group interaction: p. 0.05). For ADP-stimulated respiration rates differences
between samples were assessed using paired sample t-test (* p , 0.05 AngII vs controls for comparisons of complexes I, II and IV).
www.nature.com/scientificreports
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bands at various molecular weights, and immunoprecipitates several
unrelated proteins from liver mitochondrial fractions, as identified
by mass spectrometry. The mitochondrial immunogold and immu-
nofluorescence labelling results reported by Abadir et al. should thus
be interpreted with significant caution. Moreover, the study applied
only CGP 42112, an AT2R agonist, which has been reported to
antagonise the AT1R as well45, and functional impacts of natural
AT receptor ligands were not demonstrated.
Altogether, our results rule out the generalised presence of RAS in
mitochondria as well as the direct action of intracrine AngII on the
organelle. Further studies of other tissues, and of human origin, are
required in order to assess mitochondria as specific targets of phar-
macological interventions aimed at modifying the pathological
effects of RAS.
Methods
Reagents and antibodies. AngII was purchased from Alexis Biochemicals (UK and
Switzerland). [125I]Tyr4-Angiotensin II (2200 Ci/mmol, 81.4 TBq/mmol) was from
PerkinElmer (Cambride, UK). Primary antibodies were from Santa Cruz
Biotechnology, Inc. (Heidelberg, Germany; AT1R: sc1173, rabbit; AT2R: sc9040,
rabbit; ACE: C-20 sc-12187, goat; grp75: sc1058, goat) and New England Biolabs
(Hitchin, UK; CoxI: 4850; mouse). All HSP conjugated secondary antibodies were
from Thermo Scientific (Northumberland, UK). All other chemicals if not otherwise
specified were from Sigma-Aldrich (UK and Switzerland).
Subcellular fractionation.Mitochondrial isolation for respirometry. Isolation of liver
mitochondria was performed immediately after tissue harvesting at 4uC using
differential centrifugation46. The excised livers were immersed in ice-cold liver
isolation buffer (mannitol 220 mM, sucrose 70 mM, morpholinopropane sulfonic
acid 5 mM, pH 7.4) andminced with scissors, and homogenized in a Potter-Elvehjem
homogenizer. The homogenate was then centrifuged for 10 minutes at 700 g. The
supernatant was collected and centrifuged 3 times for 10 minutes at 7,000 g. The
pellets were then used at a final concentration of 50–100 mg protein/ml. Protein
concentration was determined using the Quant-iTTM protein assay kit (Qubit
fluorometer, Invitrogen).
Isolation of other subcellular fractions for Western blot analysis. All isolation steps,
including centrifugation were carried out at 4uC. Livers from 12 week old male
Sprague-Dawley rats were excised and placed in ice cold isolation medium (mannitol
250 mM, HEPES pH 7.4 5 mM, EGTA 0.5 mM) before mincing and washing in
isolation solution supplemented with a protease inhibitor cocktail, followed by
homogenization in a Potter-Elvehjem homogenizer. The homogenate was centri-
fuged at 800 g for 10 minutes resulting in the nuclear pellet and post nuclear
supernatant. The supernatant was centrifuged at 10,300 g for 10 minutes resulting in
the crude mitochondrial pellet and post-mitochondrial supernatant. This supernat-
ant was then centrifuged at 25,000 g for 30minutes giving a lysosomal pellet. All these
steps were performed using a Beckman J2-MCCentrifuge with a JA-20 rotor. Finally,
the supernatant was centrifuged at 100,000 g for 1 hour (Beckman 70 ultracentrifuge
with a 70.1 Ti rotor) to produce themicrosomal pellet and a cytosolic supernatant. All
pellets were resuspended in 500 ml of isolation medium before snap freezing in liquid
nitrogen and storing at 280uC.
Isolation of pure mitochondria (PM) and mitochondrial associated membranes
(MAM). A Percoll density gradient separation protocol was used to separate PM
from MAM as previously described24. In short, crude mitochondria were prepared
as described above and then layered on a column of 30%Percoll before centrifuging at
95,000 g for 40 minutes (Beckman L-70 Ultra-Centrifuge with an SW41 rotor). The
two bands (upper band MAM, lower band PM) were then further purified at 6300 g
for 10 min (Beckman J2-MC Centrifuge; JA20.1 rotor) and the pellet (PM) and
supernatant collected (MAM). The purified MAM were then pelleted by centrifu-
gation at 100,000 g for 1 hr (Beckman L-70 Ultra-Centrifuge with 70.1 Ti rotor) and
the pellets were resuspended in 500 ul of buffer.
Immunoprecipitation and western blotting. For immunoprecipitation of ACE,
samples and antibodies were processed using Pierce Crosslink IP kit (Cat. No.26147;
Thermo Scientific, Northumberland, UK), according to the recommended protocol,
with all steps carried out at 4uC and all centrifugations at low speed (3000 g) for 30–60
seconds. 10 mg ACE C-20 antibody was crosslinked to the protein A/G agarose resin
and 1 mg protein was used as input. The immunoprecipitation was performed either
in Tris-Buffered Saline, (TBS, 0.025 M Tris, 0.15 M NaCl; pH 7.2) or TBS
supplemented with 0.5 mM EDTA, 0.5% NP-40, 2.5% glycerol to promote ACE
binding.
For immunoprecipitation of AT1R and AT2R, samples were solubilized using ice-
cold buffer (50 mM HEPES, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 1 mM
Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 30 mM PyroPO4, 10 mM NaF, and
1 mg/ml bacitracin) and lysates were centrifuged at 14,000 rpm for 30 min. The
supernatants (400 mg of total protein) were first pre-cleared with equilibrated protein
G sepharose beads (GE Healthcare, Chalfont St Giles, UK) and then incubated with
2 mg antibody overnight at 4uC. Immune complexes were precipitated with protein G
sepharose beads, washed three times with ice-cold buffer and heated at 95uC for
5 min in loading sample buffer.
Proteins were resolved using 10% or 4–12% NuPAGE bis-tris gels (Invitrogen).
Gels were transferred to nitrocellulose (Hybon-C-Super, Amersham) or PVDF
membranes (Millipore, Billerica, MA, USA) using a Transblot electro-transfer
apparatus (Bio-Rad). Tomaintain integrity of IgG at 130 kDa (Fig. 3), we used a non-
denaturating 43 loading buffer without dithiothreitol and b-mercaptoethanol
(200 nM Tris HCl pH 6.8, 8% SDS, 40% glycerol, 0.1% bromophenol blue). For
immunoblotting, membranes were blocked with 5% BSA diluted in PBS containing
0,1% tween (PBST) and probedwith specified primary antibodies in 2,5%BSAdiluted
in PBST. Alternatively membranes were blocked in PBS 1 0.05% Tween (PBST) 1
5% fat-free milk and incubated overnight in primary antibody at 4uC. Blots were then
washed and incubated with HRP-conjugated secondary antibodies (Amersham).
Immunoreactive bands were detected an enhanced chemiluminescence detection kit
(Pierce, Rockford, IL, USA).
Mass spectrometry. For protein identification, samples from the
immunoprecipitations, as well as purified CM, MAM and PM fractions were
separated onNuPAGE 10% or 4–12% gels (Invitrogen), respectively, and stainedwith
Coomassie blue according to standard protocols. Proteins were identified by liquid
chromatography and tandem mass spectrometry (LC-MS/MS) and MS/MS spectra
search at the Taplin Biological Mass Spectrometry Facility (Harvard Medical School,
Boston, MA, USA) as previously described47. Proteins with three or more unique
peptide matches were considered for further bioinformatics analysis.
Bioinformatic analysis. GO terms related to angiotensin were found using
amiGO (http://amigo.geneontology.org/cgi-bin/amigo/go.cgi), all the gene names
in these GO terms were also collected. The biomaRt R package (http://www.
bioconductor.org/packages/2.11/bioc/html/biomaRt.html) was then used to find the
UniProt gene names from both the GO terms and the gene names for each species.
Additionally the GO terms were also used in Uniprot directly (http://www.uniprot.
org/) to find the UniProt gene names for each species. These 3 lists were then
combined to give as complete a list for angiotensin genes as possible. This list was then
compared to known mitochondria genes from the MitoCarta and MitoMiner
databases as well as the groups identified bymass spectrometry inMAM,CMand PM
fractions.
Measurement of mitochondrial respiration. Isolated mitochondria were
resuspended in respiration buffer (110 mM sucrose, 0.5 mM EGTA, 3.0 mMMgCl2,
80 mM KCl, 60 mM K-lactobionate, 10 mM KH2PO4, 20 mM taurine, 20 mM
HEPES, 1.0 g/l BSA, pH 7.1) at a concentration of 0.8 mg/ml and incubated with the
AngII (1 mM) for 20 min on ice, and respiration rates weremeasured at 37uCwith the
High Resolution Oxygraph (OROBOROS; Oxygraph-2k, Graz, Austria). Maximal
oxidative capacities were determined in the presence of saturating concentrations of
oxygen, ADP (0.25 mM) and specific mitochondrial substrates. For complex I-
dependent respiration, substrates were glutamate (10 mM) plus malate (5 mM). For
measurement of complex II-dependent respiration, rotenone (0.5 mM) and succinate
(10 mM) was used. Complex IV-dependent respiration was measured with ascorbate
(4 mM) and N,N,N9,N-tetramethyl-p-phenylendiamine (TMPD, 0.5 mM). Sodium
azide (5 mM) was used to measure autooxidation. Oxygen consumption is expressed
as pmol 3 s21 3 mg mitochondrial protein21.
Radioligand binding assays. Saturation binding. For saturation binding,
mitochondrial homogenate preparations from n 5 3 rat livers were assayed in
separate experiments. Homogenates (100 mL) were incubated in assay buffer
(NaH2PO4, 50 mM; NaCl, 100 mM; EGTA, 1 mM; MgCl2, 10 mM; BSA, 0.2%; pH
7.4) with increasing concentrations (15 pM-2 nM) of [125I]-AngII (in a final volume
of 200 mL) for 1 h at room temperature (22 uC). Unlabelled AngII (10 mM) was used
to determine non-specific binding at each concentration in duplicate tubes.
Homogenates were centrifuged (20,000 g, 10 min, 4 uC) to break equilibrium, pellets
re-suspended in 500 mL ice-cold Tris-HCl (50 mM, pH 7.4) buffer to remove
unbound ligand and centrifuged as previously. Resulting pellets were counted in a
gamma counter. Data from these experiments were analysed using the iterative non-
linear curve fitting programs Kinetic and Ligand (KELL package, Elsevier Biosoft,
Cambridge, U.K.) to determine the equilibrium dissociation constant (KD) and
maximal receptor density (Bmax) and Hill slope (nH).
Fixed concentration competition assays. For fixed concentration competition assays,
pooled (n5 5 rat livers)MAMhomogenate preparationswere individually assayed (n
5 5 assays) each with 3 to 6 replicate assay points. Homogenates (100 mL) were
incubated in assay buffer as previously with 0.5 nM [125I]-AngII (in a final volume of
200 mL) for 1 h at room temperature (22 uC), with or without the addition of
Angiotensin-II (10 mM) to determine non-specific binding. Additionally, either
Losartan (1 mM) or PD123319 (1 mM) were included to determine presence of AT1
vs. AT2 receptors. Graphs were prepared to show reduction of specific binding
achieved by each competing compound.
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Statistical Analysis. Mitochondrial respiration rates were assessed by analysis of
variance (ANOVA). The Statistical Package for Social Sciences version 18.0 (SPSS,
Chicago, IL) was used for statistical analysis.
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